Outset Medical, Inc. (OM)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 36/100 (MEDIUM), 13.7 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 5.71% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Despite Fast-paced Momentum, Outset Medical (OM) Is Still a Bargain Stock
- Outset Medical (OM) Q2 2026 Earnings Call Transcript
- Outset Medical Q2 Earnings Call Highlights
- Outset Medical Inc (OM) (Q2 2026) Earnings Call Highlights: Revenue Growth and Strategic HCA ...
- Outset Medical Reports Second Quarter 2026 Results
- Outset Medical to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
- Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Outset Medical (OM) Surges 25.6%: Is This an Indication of Further Gains?
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Outset Medical, Inc..
Full OM Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.